abstract |
The invention relates to novel compounds having formula (I) n n nwherein Cy, X, Y, L and R 1-6 are as defined herein. The compounds bind CD11/CD18 adhesion receptors such as Lymphocyte Function-associated Antigen-1 (LFA-1) and are therefore useful for treating disorders mediated by LFA-1 such as inflammation and autoimmune diseases. |